Join the Rise in Next-Gen Therapeutics
Investor Relations
Innovative Genetics™ is a BioIP infrastructure company built for the Regulated Therapeutics Economy. We license proprietary formulations, brand IP, and compliant infrastructure—scaling the commercialization of next-gen therapeutics without cultivation, federal exposure, or capital-heavy overhead.
We are currently raising capital to accelerate U.S. expansion and prepare for a
public-market transition.
Innovative Genetics™ is a BioIP infrastructure company built for the Regulated Therapeutics Economy. We license proprietary formulations, brand IP,
and compliant infrastructure—scaling the commercialization of next-gen therapeutics without cultivation, federal exposure,
or capital-heavy overhead.
We are currently raising capital to accelerate U.S. expansion and prepare for a
public-market transition.
Join the Rise in Next-Gen Therapeutics
Investor Relations
Innovative Genetics™ is a BioIP infrastructure company powering the Regulated Therapeutics Economy. We license proprietary formulas, brand IP, and compliant infrastructure to scale next-gen therapeutics—without cultivation or federal risk. Now raising capital to accelerate U.S. growth and prepare for public markets.
Million Dollar Target
Million Dollar Target
Million Dollar Target
Current Raise
Current Raise
Round: Seed+ (Open)
Round: Seed+ (Open)
Million Pre-Money Valuation
Million Pre-Money Valuation
Million Pre-Money Valuation
Structure: SAFE w/ valuation cap or priced equity
Status: Accepting strategic partners (Q2–Q3 2025)
Use of Funds
Use of Funds
Expand infrastructure footprint in 12 additional U.S. states
Expand infrastructure footprint in 12 additional U.S. states
Expand infrastructure footprint in 12 additional U.S. states
Advance IP licensing and packaging operations
Advance IP licensing and packaging operations
Advance IP licensing and packaging operations
Finalize strategic operator M&A agreements
Finalize strategic operator M&A agreements
Finalize strategic operator M&A agreements
Prepare public-market readiness (legal, finance, IR)
Prepare public-market readiness (legal, finance, IR)
Prepare public-market readiness (legal, finance, IR)
- $0
Billion+ U.S. TAM by 2032 (Cannabis + Psychedelic Therapeutics)
- 0
+ trademarked brands
- 0
state infrastructure expansion pipeline
- $0
Billion+ U.S. TAM by 2032 (Cannabis + Psychedelic Therapeutics)
- 0
+ trademarked brands
- 0
state infrastructure expansion pipeline
Why We Win
Why We Win
Why We Win
The BioIP Opportunity
The BioIP Opportunity
Public-market–ready structure with no 280E or federal risk
Public-market–ready structure with no 280E or federal risk
Recurring revenue model via IP royalties + lease income
Recurring revenue model via IP royalties + lease income
Exclusive buyout rights embedded in partner agreements
Exclusive buyout rights embedded in partner agreements
- $0
Billion+ U.S. TAM by 2032 (Cannabis + Psychedelic Therapeutics)
- 0
+ trademarked brands
- 0
state infrastructure expansion pipeline
Public-market–ready structure with no 280E or federal risk
Public-market–ready structure with no 280E or federal risk
Recurring revenue model via IP royalties + lease income
Recurring revenue model via IP royalties + lease income
Exclusive buyout rights embedded in partner agreements
Exclusive buyout rights embedded in partner agreements
Traction Metrics
- $12M+ Active Commercial Pipeline
- 10,000+ SQFT leased production
infrastructure (2024)
- 64+ formulation SKUs commercialized
- Strategic partners in Oregon, California,
Colorado, New York, Florida
Traction Metrics
- $12M+ Active Commercial Pipeline
- 10,000+ SQFT leased production
infrastructure (2024)
- 64+ formulation SKUs commercialized
- Strategic partners in Oregon,
California, Colorado, New York, Florida
Request Full Investor Access
Fill out the form below to gain full access to our DataRoom and view in-depth information on our business goals and strategies.
Request Full Investor Access
Fill out the form below to gain full access to our DataRoom and view in-depth information on our business goals and strategies.
Request
Full Investor Access
Fill out the form below to gain full access to our DataRoom and view
in-depth information on our business goals and strategies.